T cell receptor β-chain repertoire analysis of tumor-infiltrating lymphocytes in pancreatic cancer

Can Cui1 | Xiuyun Tian1 | Jiahui Wu1 | Chaoting Zhang2 | Qin Tan3 | Xiaoya Guan1 | Bin Dong4 | Min Zhao5 | Zheming Lu2 | Chunyi Hao1

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, China
2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China
3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, China
4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, China
5Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China

Correspondence
Zheming Lu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China. Email: zheminglu@163.com and Chunyi Hao, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, China. Email: haochunyi@bjmu.edu.cn

Funding information
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (approval No. XMLX201708); Capital Health Research and Development Special (approval No. 2016-2-2151); Beijing Municipal Administration of Hospital’s Ascent Plan (approval No. DFL20181104); National Natural Science Funding (approval No. 31770836 and 81673500), Capital Characteristic Clinical Application Research (approval No.: Z161100000516065); Open Project funded by Key laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (approval No. 2017 Open Project-7).

Pancreatic cancer is lethal due to lack of perceptible symptoms and effective treatment methods. Immunotherapy may provide promising therapeutic choices for malignant tumors like pancreatic cancer. Tumor-infiltrating lymphocytes (TIL) in tumor mesenchyme could recognize peptide antigens presented on the surface of tumor cells. The present study aimed to test the relationship between the T cell receptor (TCR) β repertoire of the tumor and peripheral blood, and also to investigate the intra-tumor spatial heterogeneity of the TCR β repertoire in pancreatic cancer. To the best of our knowledge, this is the first study to evaluate the clonal composition of TCR β repertoire in TIL across the spatial extent of pancreatic cancer. In this study, we studied 5 patients who were diagnosed with primary pancreatic cancer. Ultra-deep sequencing was used to assess the rearrangement of the TCR β-chain (TCR(β)) gene. HE staining and immunohistochemistry of CD3, CD4, CD8 and HLA class I were used to show histopathology and immune conditions macroscopically. TIL repertoire showed that different regions of the same tumor showed a greater number of repertoire overlaps between each other than between peripheral blood, which suggested that T cell clones in pancreatic cancer might be quite different from those in peripheral blood. In contrast, intra-tumor TCR β repertoires were spatially homogeneous between different regions of a single tumor tissue. Based on these results, we speculated that the cellular adaptive immune response in pancreatic cancer was spatially homogeneous; this may pave the way for immunotherapy for the treatment of pancreatic cancer patients.

KEYWORDS
immunohistochemistry, intra-tumor spatial heterogeneity, pancreatic cancer, T cell receptor, ultra-deep sequencing
INTRODUCTION

Pancreatic cancer is the fourth leading cause of cancer-associated deaths worldwide, and its poor prognosis can be ascribed to its malignant biological behavior and few detectable symptoms in the early stages. A study on familial pancreatic cancer demonstrated that pancreatic cancer might show heterogeneity in numerous gene deletions and amplifications. Pancreatic cancer has been proved to be genetically heterogeneous based on the therapeutic effects seen in primary tumors and during metastases. Therefore, personalized treatment for pancreatic cancer is essential owing to its heterogeneity.

Immunotherapeutic methods such as adoptive cell therapy (ACT) and the use of immune checkpoint inhibitors (such as inhibitors of CTLA4, PD-1 and PD-L1) have been shown to produce durable responses in the treatment of some solid tumors. Increased numbers of tumor-infiltrating lymphocytes and improved survival in several types of tumors, including pancreatic cancer, could be correlated. In Diana et al. (2016), pancreatic cancer patients with higher numbers of CD8+ and PD-1+ tumor-infiltrating lymphocytes (TIL) showed significantly superior overall survival (OS). Several other reports also demonstrated that high numbers of CD8+ and low numbers of Foxp3+ T cells correlated with better clinical outcomes in patients with resectable primary pancreatic cancer. CD4/8(+/+) status is an independent favorable prognostic factor for pancreatic cancer patients. This suggests that TIL directed against tumor antigens may play a significant role in targeting tumor cells. Moreover, whether the biopsy of a single tumor portion might represent the immune condition of the entire tumor tissue remains to be elucidated.

The clonal composition of TIL can be assessed by analyzing the TIL repertoires generated by somatic recombination of the T cell receptor (TCR) α- and β-chains. Rearrangement of the V (variable), D (diversity), and J (joining) segments of the TCR β chain generates the highly variable complementary determining region 3 (CDR3), which is critical for determination of the specificity of each T cell clone. Therefore, ultra-deep sequencing of the TCR β CDR3 region might help in approximately assessing the clonal composition of TIL.

In addition, T cell infiltrates might be uniform or heterogeneous across different regions of the same tumor. The heterogeneity is probably driven by intra-tumoral competition and selection by the host's immune response to tumor therapeutics. It is necessary to assess the clonal composition of TIL across the spatial extent of the entire tumor to examine whether different parts of the tumor have different types of clones. Meanwhile, several studies have investigated the heterogeneity of TCR repertoires in different regions of the same tumor, and the conclusions seem controversial in different types of tumors. Thus, the clonal composition of TIL in different tumors may be distinct. In addition, Bai et al. (2015) reveal that both the tumor tissue and blood from pancreatic cancer patients show little similarity with that from healthy individuals, which implies that the immune condition is altered in pancreatic cancer. Therefore, it is essential to assess the clonal composition of TIL in pancreatic cancer owing to its complexity.

To determine the antigen receptor repertoire of TIL in pancreatic cancer, we collected multiple tumor samples from different regions of the same tumor and peripheral blood from 5 primary pancreatic cancer patients at the same time. Then, we performed deep sequencing for the TCR β CDR3 region using these samples, to test the relationship between the TCR β repertoire of the tumor and peripheral blood, and also to investigate the intra-tumoral spatial heterogeneity of the TCR β repertoire in pancreatic cancer. We performed HE staining and immunohistochemistry of CD3, CD4, CD8 and HLA class I to evaluate the histopathology and immune condition of the tumor tissue. To the best of our knowledge, this is the first study to evaluate the TCR β clonal composition of TIL across the spatial extent of pancreatic cancer.

MATERIALS AND METHODS

2.1 Patients and samples

Tumor tissues and peripheral blood were obtained from 5 patients who were diagnosed with pancreatic cancer and received surgical resection at Peking University Cancer Hospital, Beijing, China. None of these 5 patients had received chemotherapy or radiotherapy before surgery. The tumor samples were collected immediately after resection, and we collected 4 or 5 samples from different regions to represent the spatial heterogeneity of the entire tumor. Each region was cut into 2 parts, 1 for DNA extraction and the other for immediate formalin fixation. Images of the tumor samples are shown in Figure S1. For each patient, the sample named “T1” was taken from the center of the entire tumor tissue, and the other samples were taken from the surrounding areas. Peripheral blood was drawn at the time of surgery into EDTA-coated tubes prior to administration of anesthesia. DNA was extracted from fresh tumor tissues using the EasyPure Genomic DNA Kit (Transgen Biotech, Beijing, China), and DNA from blood cells was isolated using the Whole Blood Genomic DNA Kit (BioTeke Corporation, Beijing, China) following the manufacturer's instructions. Moreover, ultra-deep TCR sequencing allows the analysis of the T cell repertoire using DNA extracted from samples without prior separation of the T cell population. Table 1 shows the details and number of samples from each patient. DNA from the 4 tumor samples from patient 1 was amplified using PCR and sequenced in duplicates (T1A and T1B: duplicate samples of T1; T2A and T2B: duplicate samples of T2; T3A and T3B: duplicate samples of T3; T4A and T4B: duplicate samples of T4). Patient 1A included T1A, T2A, T3A, T4A and peripheral blood of patient 1. Patient 1B included T1B, T2B, T3B, T4B and peripheral blood of patient 1. This study was approved by the Ethical Committee from Peking University Cancer Hospital, and written informed consent was provided by each patient prior to initiation. A diagram of our experimental program is shown in Figure 1.
2.2 | High-throughput sequencing

The TCR β CDR3 region was amplified using Multiplex PCR to obtain the region of the antigen receptor gene, and the TCR β CDR3 region was sequenced using Illumina NextSeq 500 (MyGenostics, Beijing, China). Sequencing reads were identified according to the definition established by the International ImMunoGeneTics (IMGT) collaboration. Sequencing reads that did not match the canonical structure of CDR3 sequences were not used for subsequent analysis. A standard algorithm was used to identify which V, D and J segments contributed to each TCR β CDR3 sequence.

2.3 | CDR3 sequence analysis

To evaluate the similarity between the TCR β repertoires of samples within the same tumor and between those of the tumor and peripheral blood, we used the metric of TCR β repertoire overlap. For example, for 2 samples, a and b, we identified n as TCR β CDR3 sequences present in both samples, and C as the sequencing read counts for each sequence in each sample. Meanwhile, the TCR β repertoire overlap was defined as the sum of the sequencing reads of shared TCR β sequences in both samples divided by the sum of sequencing reads observed in these 2 samples, which ranged from 0 to 1. The formula used for calculation is:

| TABLE 1 | Sample information of 5 pancreatic cancer patients |
|----------|--------------------------------------------------|
| Patient  | Gender | Age   | Size of tumor | Site of tumor | Differentiation and/or pathology | Stage of tumor | Tumor samples | Blood |
| Patient1 | Female | 66    | 5 * 2 * 2 cm  | Neck of pancreas | Moderate differentiation, adenocarcinoma | T3N0M0 | T1,T2, T3, T4 | B     |
| Patient2 | Male   | 64    | 4 * 4 * 3 cm  | Body and tail of pancreas | Moderate differentiation, adenocarcinoma | T3N1M0 | T1,T2, T3, T4, T5 | B     |
| Patient3 | Female | 79    | 4.5 * 3.5 * 3 cm | Neck and body of pancreas | Moderate differentiation, adenocarcinoma | T3N0M0 | T1,T2, T3, T4, T5 | B     |
| Patient4 | Male   | 73    | 6 cm (the maximum diameter) | Head of pancreas | Adenosquamous carcinoma | T3N1M0 | T1,T2, T3, T4, T5 | B     |
| Patient5 | Male   | 56    | 3 * 3 * 2 cm  | Head of pancreas | Moderate differentiation, adenocarcinoma | T3N1M0 | T1,T2, T3, T4 | B     |

FIGURE 1  Diagram showing our experimental program. Four or five different regions of 1 single tumor were collected immediately after surgical resection. Peripheral blood was drawn at the time of surgery into EDTA-coated tubes prior to anesthesia. DNA from both tumor tissue and peripheral blood was extracted for T cell receptor (TCR) repertoire sequencing. Ultra-deep TCR sequencing allows the analysis of the T cell repertoire directly from DNA extracted from samples without prior separation of the T cell population. We divided each tumor tissue into 2 parts, 1 for DNA extraction and the other for immediate formalin fixation. These samples were used for HE staining and immunohistochemistry of CD3, CD4, CD8 and HLA class I.
2.4 | Immunohistochemistry

The 4-μm thick tissue sections were baked at 72°C for 1 hour, and then dewaxed in xylene and rehydrated in graded alcohol concentrations. Hydrogen peroxide (3%) was used to block the activity of endogenous peroxidase for 15 minutes. Antigen retrieval was performed in a pressure cooker after 3 PBS washes. Upon cooling to room temperature, sections were blocked using corresponding blocking solution for 1 hour at 37°C. Then, the sections were incubated with the primary antibody at a suitable dilution overnight at 4°C. The following day, the ready-to-use EnVision regent (EnVision detection system peroxidase/DAB; rabbit/mouse; Dako, Glostrup, Denmark) was used to bind the primary antibody. 3,3′-Diaminobenzidine tetrahydrochloride (Dako, Glostrup, Denmark) was used to visualize the reaction. Then, the sections were counterstained with hematoxylin and dehydration was performed in the sequence of graded alcohol concentrations and xylene. The detailed experimental methods and information regarding the primary antibody are shown in Table S1.

2.5 | Statistical analysis

Statistical analyses were performed using the SPSS software, version 13.0 (SPSS, Chicago, IL, USA). Unpaired t test and nonparametric tests were used depending on the category of data. A 2-sided P-value < .05 was considered statistically significant.

3 | RESULTS

3.1 | High-throughput sequencing of T cells

We used Multiplex PCR to amplify the TCR β CDR3 region and then used high-throughput sequencing to examine the sequence of the TCR β CDR3 region. As shown in Table 2, we detected approximately 2.09 million sequence reads on average, distributed among an average of 15,646 unique TCR β CDR3 rearrangements in tumor tissue samples from 5 patients. The average unique TCR β reads in tumor tissue samples were less than those in blood samples (15,646 ± 5984 vs 23,838 ± 7944, unpaired t test, and P = .012). The average fraction of the top 100 TCR β sequence was 50.2% in tumor samples and 33.7% in peripheral blood samples, respectively (unpaired t test, P < .001). The results of clonality which reflected the diversity of T cell clones showed that the TCR β repertoires of tumor tissues had fewer clonotypes than in their matched peripheral blood (average clonality was .55 in tumor tissues and average clonality was .49 in peripheral blood; P = .035 using the nonparametric test). These results showed that TCR β repertoires in pancreatic tumor tissues were more oligoclonal.

3.2 | Spatial homogeneity of T cell clones within a single tumor

We used the TCR β repertoire overlap and the distance metric to evaluate the heterogeneity or homogeneity among different tumor regions, and between the tumor and peripheral blood samples.

However, the noise inherently found in sampling randomly from a diverse population might cause random sampling error even if we only analyze the top 100 T cell clones. Thus, to evaluate the interference of sequencing error and sampling noise caused by sequencing, we performed duplicate PCR reactions in 4 tumor samples of patient 1. Using replicate PCR reactions, the only factor that influenced the TCR β overlap metric was technical error and sampling noise.19

As shown in Figure 2, the TCR β repertoire overlap illustrated that different regions of the same tumor showed much more repertoire overlaps with each other than with peripheral blood. Moreover, dendrograms clearly show that peripheral blood was quite distant from tumor samples (shown in Figure 3). These results indicated that different tumor regions shared more TCR β sequences with each other than with corresponding peripheral blood.

We also compared the average TCR β overlap of duplicate samples (Duplicate T), tumor tissues (T and T) and tumor tissues vs peripheral blood (T and B), as shown in Figure 4; we found that the average TCR β overlaps of “T and T” were not significantly lower than
TCR β overlaps of “Duplicate T” (unpaired t test, \(P = .104\)), whereas there were significant differences in the average TCR β overlaps of “T and T” vs “T and B” (nonparametric test, \(P < .001\)), as well as in the average TCR β overlaps of “Duplicate T” vs “T and B” (unpaired t test, \(P = .001\)). These results demonstrated that the T cell response within pancreatic cancer was homogeneous across the spatial extent in 1 single tumor.

To further evaluate the degree of spatial heterogeneity of the T cell response in pancreatic cancer, we classified sequences into ubiquitous and heterogeneous sequences. Heat maps were constructed to show the frequencies of each ubiquitous and heterogeneous clone in each sample (shown in Figure 5). Heat maps for regional abundance of the top 100 T cell clones in all samples showed that T cell clones in different regions of a single tumor were spatially homogeneous, especially in clones with high frequencies.

### 3.3 HE staining and immunohistochemistry of CD3, CD4, CD8 and HLA class I

Figures 6 and S6-S9 showed HE staining and representative immunohistochemical staining images of CD3, CD4, CD8 and HLA

---

**TABLE 2** T cell receptor (TCR) β CDR3 sequencing metrics in 5 patients

| Patient | Region⁶ | Productive TCR β reads | Unique TCR β reads | Highest frequency clone (%) | Top 100 clones (%) | Clonality |
|---------|---------|------------------------|--------------------|-----------------------------|-------------------|-----------|
| Patient 1 | T1A     | 1,525,728              | 11,186             | 8.68                        | 48.47             | .54       |
|          | T1B     | 1,799,768              | 12,818             | 7.64                        | 46.38             | .54       |
|          | T2A     | 1,779,081              | 13,835             | 10.51                       | 48.29             | .54       |
|          | T2B     | 1,951,744              | 14,045             | 9.98                        | 48.33             | .54       |
|          | T3A     | 2,357,465              | 18,481             | 12.96                       | 48.42             | .54       |
|          | T3B     | 2,525,659              | 21,760             | 11.60                       | 45.58             | .54       |
|          | T4A     | 1,804,027              | 13,281             | 8.97                        | 44.68             | .53       |
|          | T4B     | 2,382,890              | 16,738             | 7.58                        | 41.48             | .52       |
|          | B       | 2,551,761              | 28,421             | 3.54                        | 28.84             | .46       |

| Patient 2 | T1     | 1,467,014              | 8886               | 4.22                        | 56.00             | .56       |
|           | T2     | 1,818,896              | 14,242             | 4.51                        | 47.04             | .53       |
|           | T3     | 654,888                | 4947               | 7.63                        | 61.22             | .57       |
|           | T4     | 1,243,241              | 6960               | 3.92                        | 54.49             | .56       |
|           | T5     | 935,497                | 5755               | 8.66                        | 63.73             | .59       |
|           | B      | 1,556,359              | 11,729             | 34.63                       | 53.44             | .61       |

| Patient 3 | T1     | 1,438,610              | 13,834             | 6.01                        | 47.76             | .52       |
|           | T2     | 2,145,798              | 24,214             | 6.41                        | 38.33             | .49       |
|           | T3     | 2,232,971              | 14,612             | 7.44                        | 52.46             | .56       |
|           | T4     | 1,986,334              | 16,015             | 2.77                        | 44.26             | .51       |
|           | T5     | 2,052,436              | 15,550             | 6.41                        | 50.22             | .54       |
|           | B      | 2,643,033              | 32,898             | 12.07                       | 36.64             | .49       |

| Patient 4 | T1     | 3,101,702              | 21,685             | 7.84                        | 58.18             | .58       |
|           | T2     | 3,127,847              | 32,022             | 4.17                        | 40.37             | .50       |
|           | T3     | 3,385,193              | 19,232             | 9.04                        | 56.33             | .59       |
|           | T4     | 3,400,284              | 20,930             | 10.97                       | 60.96             | .60       |
|           | T5     | 2,857,367              | 23,608             | 7.87                        | 54.46             | .56       |
|           | B      | 2,070,463              | 23,945             | 1.58                        | 20.61             | .44       |

| Patient 5 | T1     | 2,106,881              | 14,340             | 4.41                        | 47.92             | .54       |
|           | T2     | 1,823,809              | 17,671             | 5.12                        | 45.51             | .52       |
|           | T3     | 2,365,188              | 11,934             | 9.55                        | 59.11             | .59       |
|           | T4     | 2,241,304              | 13,855             | 3.93                        | 44.81             | .54       |
|           | B      | 1,555,349              | 22,197             | 4.61                        | 29.10             | .45       |

⁶T1A and T1B: duplicate samples of T1; T2A and T2B: duplicate samples of T2; T3A and T3B: duplicate samples of T3; T4A and T4B: duplicate samples of T4.
class I of corresponding tumor tissues. CD3, CD4 and CD8 expression were localized mainly on the plasma membrane of T cells in the mesenchyme of the tumor tissue. Staining of CD3, CD4 and CD8 could roughly represent the quantity of T cells in the mesenchyme of tumor tissue. CD3, CD4 and CD8 expression were mostly seen scattered throughout the tumor while...
occasionally in clusters. HLA class I staining was seen in the tumor cell membrane and cytoplasm. The antibody for HLA class I reacts with the heavy chains of human HLA class I A, B and C. Each tumor tissue showed moderate or strong expression of HLA class I.

4 | DISCUSSION

Immunotherapy is a novel method used in fundamental and clinical pancreatic cancer research. Some progress has been made, such as the development of adoptive T cell therapy.30,31 T cells can
FIGURE 5  Heat maps showing regional abundance of top 100 T cell clones of all samples. Heat maps revealed the regional frequencies of the top 100 T cell clones. The colors of each grid that represent different tumor regions of 1 patient are similar to each other. Results show that the T cell clones in different regions of a single tumor are spatially homogeneous, especially in clones with high frequencies.
infiltrate solid tumors, and the adaptive immune system is mediated by TIL in order to respond to solid tumors. Different kinds of TIL which might direct the behavior of tumor cells may influence clinical outcomes.

In this study, to investigate the heterogeneity or homogeneity of TIL across different regions of the same tumor in pancreatic cancer, we evaluated the characteristics of TIL in primary pancreatic cancer using ultra-deep sequencing for the rearranged TCR β gene. We found that different regions of the same tumor showed more repertoire overlaps with each other than with peripheral blood, which suggested that TCR β repertoires in TIL of tumor tissues were quite different from circulating T cells. Some studies have reported similar results, and in the present study, we have further confirmed the difference between TIL of tumor tissues and circulating T cells in pancreatic cancer. This suggested that T cell clones within pancreatic cancer predominantly react to tumor antigens and that T cells in tumor tissue do not circulate throughout to peripheral blood.

We investigated the clone types of these TIL. We found that intra-tumoral TCR β repertoires of different regions in 1 single tumor were spatially homogeneous, which was similar with findings of studies in ovarian cancer. Moreover, there were some ubiquitous T cell clones in different tumor regions, and T cell clones in different regions of a single tumor were spatially homogeneous, especially in the clones with high frequencies, which meant that these ubiquitous T cell clones were activated by common neoantigens. Some other studies show that tumors are heterogeneous not only in cancer cells but also in TCR β repertoires. In addition, the heterogeneity may affect several aspects of the disease, such as response to therapy.

Therefore, as the intra-tumoral TCR β repertoires of the TIL population in pancreatic cancer were found to be homogeneous in a single tumor, a single biopsy of pancreatic cancer could provide sufficient information about the immune conditions of the entire tumor tissue. Furthermore, isolation of TIL specific for antigens of a random region of the tumor might facilitate effective corresponding adoptive cell therapy for patients. A study by Xueli Bai et al. shows the heterogeneity of TCR repertoires among different pancreatic cancer individuals; thus, even though TCR β repertoires of different regions in a single tumor are spatially homogeneous, personalized immunotherapy is necessary. In addition, using immune staining we also found that CD3, CD4 and CD8 expression were mostly scattered throughout the tumor tissue while occasionally in clusters in the mesenchyme of tumor tissue. This lymphocyte distribution feature was similar with some other diseases.

There are also aspects to be improved in the present study. In our work, we only chose the TCR β chain to represent all characteristics of TCR and have not considered the TCR α chain. Some other studies have demonstrated that TIL in pancreatic cancer are complicated. TIL in pancreatic cancer have unrestricted TCR Vα gene usage and contain considerable numbers of TCR γ δ T cells. Different types of TIL quantification might act as predictive biomarkers for response to immunotherapy. Therefore, even if TCR share common TCR β chains, there might be some other differences that affect the response to immunotherapy; extensive analysis might provide comprehensive results. In addition, results might be more reliable and precise if CD4+ and CD8+ T cells can be sorted using flow cytometry and then sequenced, respectively. We also need to expand the sample size to further validate our results.

In summary, to the best of our knowledge, this is the first study to evaluate the clonal composition of TIL across the spatial extent of pancreatic cancer using high-throughput TIL repertoires, and we

FIGURE 6 The HE staining and representative immunohistochemical staining images of CD3, CD4, CD8 and HLA class I in patient 1 (magnification: x200). CD3, CD4 and CD8 expression were localized mainly on the plasma membrane of T cells in the mesenchyme of the tumor tissue. Staining of CD3, CD4 and CD8 could roughly represent the quantity of T cells in the mesenchyme of tumor tissue. CD3, CD4 and CD8 expression were mostly seen scattered throughout the tumor while occasionally in clusters. HLA class I staining was seen in the tumor cell membrane and cytoplasm. Each tumor tissue showed moderate or strong expression of HLA class I.
have demonstrated that ultra-deep sequencing of the TCR gene allowed analysis of the TCR gene sequence using DNA directly extracted from pancreatic cancer tissues without prior separation of the T cell population. We found that the immune response in pancreatic cancer was distinct from the circulating immune repertoire, and that the intra-tumoral microenvironment was characterized by internally homogenous T cell repertoires. Therefore, a single biopsy of pancreatic cancer could provide sufficient information about the entire tumor. In future studies, we will also compare TCR repertoires in liver metastases or lymph node metastases with primary pancreatic cancer tissue, which could provide references for immunotherapy of advanced pancreatic cancer. A study referring to the TIL of pancreatic cancer has shown that pancreatic cancer is not an immunologically "cold" tumor, thus, if a method is developed to isolate TIL specific for antigens of a random region of the tumor, the corresponding adoptive cell therapy may be efficient for patients, which might provide a novel method for immunotherapy to treat pancreatic malignancies.

CONFLICT OF INTEREST

The authors have no conflict of interest.

ORCID

Chunyi Hao https://orcid.org/0000-0002-1233-1689

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.

2. Tan AC, Fan JB, Karikari C, et al. Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. Cancer Biol Ther. 2008;7:135-144.

3. Makohon-Moore AP, Zhang M, Reiter JG, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017;49:358-366.

4. Pedersen K, Bilal F, Bernado Morales C, et al. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene. 2017;36:5639-5647.

5. Roberts NJ, Norris AL, Petersen GM, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6:166-175.

6. Ott PA, Hodi FS, Robert C, CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300-5309.

7. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67:4-17.

8. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571.

9. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269-281.

10. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93-103.

11. Diana A, Wang LM, D’Costa Z, et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:40992-41004.

12. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434.

13. Ene-Otong A, Clear AJ, Watt J, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013;145:1121-1132.

14. Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914-923.

15. Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26-e31.

16. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334:395-402.

17. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103:1139-1143.

18. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.

19. Emerson RO, Sherwood AM, Rieder MJ, et al. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol. 2013;231:433-440.

20. Chen Z, Zhang C, Pan Y, et al. T cell receptor beta-chain repertoire analysis reveals intratumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma. J Pathol. 2016;239:450-458.

21. Gerlinger M, Quezada SA, Peggs KS, et al. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol. 2013;231:424-432.

22. Bai X, Zhang Q, Wu S, et al. Characteristics of tumor infiltrating lymphocyte and circulating lymphocyte repertoires in pancreatic cancer by the sequencing of T cell receptors. Sci Rep. 2015;5:13664.

23. Youssi Monod M, Giudicelli V, Chaume D, Lefranc MP. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics. 2004;20(suppl 1):i379-i385.

24. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:1870-1874.

25. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406-425.

26. Cooper ZA, Frederick DT, Junea VR, et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncotarget. 2013;2:e26615.

27. Liaskou E, Klemadsdal Henriksen EK, Holm K, et al. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. Hepatology (Baltimore, MD). 2016;63:1608-1619.

28. Warren RL, Freeman JD, Zeng T, et al. Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. Genome Res. 2011;21:790-797.

29. Robins H, Desmarais C, Matthys J, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods. 2012;375:14-19.

30. Koteas E, Saif MW, Syrigos K. Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol. 2016;142:1795-1805.
31. Chen L, Zhang X. Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer. *Immunotherapy*. 2016;8:223-234.
32. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. *Cancer Immunol Immunother*. 2006;55:451-458.
33. Lotzova E. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment. *Nat Immun Cell Growth Regul*. 1990;9:253-264.
34. Lee AJ, Endesfelder D, Rowan AJ, et al. Chromosomal instability confers intrinsic multidrug resistance. *Can Res*. 2011;71:1858-1870.
35. Tseng WW, Demicco EG, Lazar AJ, Lev DC, Pollock RE. Lymphocyte composition and distribution in inflammatory, well-differentiated retroperitoneal liposarcoma: clues to a potential adaptive immune response and therapeutic implications. *Am J Surg Pathol*. 2012;36:941-944.
36. Zha B, Huang X, Lin J, Liu J, Hou Y, Wu G. Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease. *J Clin Lab Anal*. 2014;28:249-254.
37. Preza GC, Yang OO, Elliott J, Anton PA, Ochoa MT. T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols. *PloS ONE*. 2015;10:e0122723.
38. Giusca SE, Wierzbicki PM, Amalinei C, Caruntu ID, Avadanei ER. Comparative analysis of CD4 and CD8 lymphocytes - evidences for different distribution in primary and secondary liver tumors. *Folia Histochem Cytoiol*. 2015;53:272-281.
39. Muller-Ostermeyer F, Ebert M, Malfertheiner P, Schubert W. T-cell receptor Valpha gene expression of infiltrating T cells in pancreatic cancer. *Scand J Gastroenterol*. 1998;33:872-879.
40. Kitayama J, Atomi Y, Nagawa H, et al. Functional analysis of TCR gamma delta+ T cells in tumour-infiltrating lymphocytes (TIL) of human pancreatic cancer. *Clin Exp Immunol*. 1993;93:442-447.
41. Ascierto PA, Kalos M, Schaer DA, Callahan MJ, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. *Clin Cancer Res*. 2013;19:1009-1020.
42. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. *Clin Cancer Res*. 2013;19:393-403.
43. Poschke I, Faryna M, Bergmann F, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. *Oncoimmunology*. 2016;5:e1240859.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.